Gilead Sciences, Inc. $GILD Shares Bought by Sagespring Wealth Partners LLC

Key Points

• Sagespring Wealth Partners LLC increased its stake in Gilead Sciences by 28.5% in Q2, holding 17,351 shares valued at approximately $1.92 million.
• Gilead reported $2.01 EPS for the previous quarter, surpassing estimates, with revenue of $7.08 billion compared to an expected $6.95 billion.
• The company declared a quarterly dividend of $0.79 per share, yielding 2.7%, with a payout ratio of 62.95%.

Sagespring Wealth Partners LLC grew its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 28.5% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 17,351 shares of the biopharmaceutical company's stock after acquiring an additional 3,848 shares during the period. Sagespring Wealth Partners LLC's holdings in Gilead Sciences were worth $1,924,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Smallwood Wealth Investment Management LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $25,000. Activest Wealth Management increased its stake in shares of Gilead Sciences by 2,837.5% during the 1st quarter. Activest Wealth Management now owns 235 shares of the biopharmaceutical company's stock worth $26,000 after purchasing an additional 227 shares in the last quarter. Goodman Advisory Group LLC purchased a new position in shares of Gilead Sciences during the 1st quarter worth approximately $29,000. Colonial Trust Advisors increased its stake in shares of Gilead Sciences by 304.3% during the 1st quarter. Colonial Trust Advisors now owns 283 shares of the biopharmaceutical company's stock worth $32,000 after purchasing an additional 213 shares in the last quarter. Finally, Core Alternative Capital increased its stake in shares of Gilead Sciences by 370.8% during the 1st quarter. Core Alternative Capital now owns 306 shares of the biopharmaceutical company's stock worth $34,000 after purchasing an additional 241 shares in the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Gilead Sciences Stock Up 0.2%

Shares of NASDAQ GILD opened at $118.48 on Wednesday. Gilead Sciences, Inc. has a 52-week low of $84.80 and a 52-week high of $121.83. The firm has a fifty day moving average of $114.84 and a 200-day moving average of $110.35. The stock has a market capitalization of $147.01 billion, a PE ratio of 23.60, a P/E/G ratio of 0.80 and a beta of 0.34. The company has a quick ratio of 1.15, a current ratio of 1.32 and a debt-to-equity ratio of 1.13.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last announced its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. Gilead Sciences had a net margin of 21.86% and a return on equity of 50.99%. The company had revenue of $7.08 billion during the quarter, compared to analysts' expectations of $6.95 billion. During the same period in the previous year, the company earned $2.01 EPS. The business's quarterly revenue was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, analysts anticipate that Gilead Sciences, Inc. will post 7.95 EPS for the current year.

Gilead Sciences Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a dividend of $0.79 per share. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences's payout ratio is currently 62.95%.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on GILD. Truist Financial raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and raised their price objective for the stock from $108.00 to $127.00 in a research note on Friday, August 8th. Royal Bank Of Canada lifted their target price on shares of Gilead Sciences from $98.00 to $100.00 and gave the stock a "sector perform" rating in a research note on Wednesday, October 8th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, September 16th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research note on Friday, September 5th. Finally, Weiss Ratings reaffirmed a "buy (b)" rating on shares of Gilead Sciences in a research note on Wednesday, October 8th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $118.08.

Insider Activity

In related news, CEO Daniel Patrick O'day sold 10,000 shares of Gilead Sciences stock in a transaction on Monday, September 29th. The shares were sold at an average price of $111.66, for a total transaction of $1,116,600.00. Following the transaction, the chief executive officer owned 591,203 shares in the company, valued at approximately $66,013,726.98. The trade was a 1.66% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction on Monday, September 15th. The shares were sold at an average price of $113.57, for a total transaction of $340,710.00. Following the transaction, the insider owned 113,193 shares in the company, valued at $12,855,329.01. The trade was a 2.58% decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,000 shares of company stock valued at $7,632,100 in the last ninety days. Company insiders own 0.27% of the company's stock.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.